AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Renin-guided Hemodynamic Management in Patients With Shock

RecruitingNAAges 18 Years - anyAllUniversitร  Vita-Salute San Raffaele
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Shock is a major risk factor for mortality among patients admitted to intensive care units (ICUs). Since various hemodynamic strategies uniformly delivered to patients with shock have failed to improve clinically relevant outcomes, individualized approaches for shock supported by robust evidence are required. This study will be a prospective, multicenter, parallel-group, single-blind, randomized controlled trial. The investigators will randomly assign 800 critically ill patients requiring norepinephrine infusion to the renin-guided or usual care groups. The investigators hypothesize that renin-guided hemodynamic management, compared to usual care, can reduce a composite of mortality and acute kidney injury (AKI) progression in patients requiring vasopressor support.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * โ‰ฅ18 years old * Admitted to an intensive care unit (ICU) * Requiring norepinephrine infusion at any dose to maintain a mean arterial pressure (MAP) of โ‰ฅ65 mmHg after initial fluid resuscitation * Expected to stay in the ICU for at least 24 hours * Written informed consent from the patient him-/herself or the patient's next of kin as requested by the ethics committee. Exclusion Criteria: * Pregnancy * Refused informed consent * Current enrollment into another randomized controlled trial that does not allow concomitant enrollment * Requiring vasopressors for \>12 hours before the enrollment * Renal failure with an imminent need for renal replacement therapy (RRT) * Intention to use RRT by clinical judgment despite lack of urgent clinical indication * AKI stage 2 and 3 at enrollment according to the KDIGO criteria * Prior enrollment in this study * Severe liver disease (Child-Pugh score \>7 points) * Chronic kidney disease (CKD) equal to or worse than CKD stage IV (eGFR \<30 mL/min/1.73 m2) * History of kidney transplant * Any condition explicitly requiring a higher or lower blood pressure target according to clinical judgment
๐Ÿ’Š

What it tests

  • Renin-guided hemodynamic management
  • Usual care
๐Ÿ“

Where

3 sites
University Hospital Dubrava
Dubrava, Croatia
Ospedale Mater Domini
Catanzaro, Italy
IRCCS Ospedale San Raffaele
Milan, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy